SERMION (NICERGOLINE) IN NEUROLOGICAL PRACTICE: THERAPEUTIC POSSIBILITIES AND FUTURE DIRECTIONS OF APPLICATION
Article Sidebar
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Main Article Content
Аннотация:
Modern medicine is faced with an ever-growing number of complex clinical cases that require an integrated approach to diagnosis and treatment. Recent studies have demonstrated a significant increase in the incidence of combined pathology, which creates additional difficulties in choosing the optimal treatment tactics and predicting disease outcomes.
Article Details
Как цитировать:
Библиографические ссылки:
Baskys A., Hou A.C. Vascular dementia: Pharmacological treatment ap- proaches and perspectives. Clin Intervent Aging 2007; 2: 327-335.
Bes A., Orgogozo J.-M., Poncet M. et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol 1999; 6: 313-322.
Caraci F., Chisari M., Frasca G. et al. Nicergoline, a drug used for age-de- pendent cognitive impairment, protects cultured neurons against β-amyloid toxicity. Brain Res 2005; 1047: 30-37.
Cattabeni F. Protein kinase C in synaptic plasticity: A molecular target in the treatment of cognitive disorders. Dement Geriat Cogn Dis 1997; 8: Suppl 1: 6-11.
Crook T.H. Nicergoline: Parallel evolution of clinical trial methodology and drug development in dementia. Dement Geriat Cogn Dis 1997; 8: Suppl 1: 22-26.
Giardino L., Giuliani A., Battaglia A. et al. Neuroprotection and aging of the cholinergic system: A role for the ergoline derivative nicergoline (Sermion). Neurosci 2002; 109: 487-497.
Nappi G., Bono G., Merlo G. et al. Long-term nicergoline treatment of mild to moderate senile dementia. Results of a multicentre, double-blind, placebo-controlled study. Clin Drug Invest 1997; 13: 308-316.
Pantoni L. Treatment of vascular dementia: evidence from trials with non- cholinergic drugs. J Neurol Sci 2004; 226: 67-70.
Rakhmonova H.N., Rakhmonov Z.M. Innervation Relationships of the Gallbladder Nerve Apparatus with Spinal and Rheumatic Nerve Ganglia (Literature Review). Eurasian Medical Research Periodical, 18, 105-108.
Rakhmonova Kh.N. Morphological bases of innervational connections of the nervous apparatus of the gallbladder Journal of Problems in Biology and Medicine, PBIM 2022 №6 (140), 387-392.
Saletu B., Anderer P., Semlitsch H.V. Relations between symptomatology and brain function in dementias: Double-blind, placebo-controlled, clinical and EEG/ERP mapping studies with nicergoline. Dement Geriat Cogn Dis 1997; 8: Suppl 1: 12-21.
Salimovna S. D. et al. Endothelial dysfunction factor as an indicator of clinical and neurological disorders in pregnant women with preeclampsia //Достижения науки и образования. – 2019. – №. 11 (52). – С. 55-60.
Takhirovna J. A., Vladimirovna S. K., Fedorovna V. N. A comprehensive approach to the diagnosis of impaired walking in patients with dyscirculatory encephalopathy //World Bulletin of Public Health. – 2023. – Т. 19. – С. 13-17.
Takhirovna JA, Vladimirovna SK, & Fedorovna VN. A comprehensive approach to the diagnosis of impaired walking in patients with dyscirculatory encephalopathy. World Bulletin of Public Health, 2023;19: 13-17.
Shmyrina K. V. et al. Experience of using gabagamma in the treatment of chronic nonspecific pain in the lower back //Medicine of Alma Ata. – 2016. – Т. 7. – №. 69. – С. 56-60.
Winblad B., Carfagna N., Bonura L. et al. Nicergoline in dementia. A review of its pharmacological properties and therapeutic potential. CNS Drugs 2000; 14: 267-287.
Winblad B., Fioravanti M., Dolezal T. et al. Therapeutic use of nicergoline. Clin Drug Invest 2008; 28: 533-552.